| ALK

Alertline

ALK's whistleblower hotline

Alertline is the name of ALK's whistleblower hotline, enabling employees, business partners and other stakeholders to report any serious and sensitive concern in a confidential and anonymous manner.


 

The ALK Alertline is a safe and confidential channel for people to speak up if they witness misconduct. It is hosted on a secure, external website to ensure confidentiality and give reporters the option to remain anonymous.

Scope
We encourage employees, suppliers, consultants or others with a work-related relationship with ALK to report reasonable suspicions regarding:

  • Breaches of applicable laws and regulations
  • Breaches of ALK’s Code of Conduct
  • Other serious offenses and concerns

The ALK Whistleblowing Policy provides detailed information and examples regarding what types of reports are in Alertline scope. It also explains the measures in place to provide a safe reporting environment for anyone who raises a concern in good faith.

Report a

concern

If you wish to file

a report, click

here.

Relevant documents
For more information, please consult our Code of Conduct and Whistleblowing Policy.
 
Last updated: 10.12.2025

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America

Last updated: 01.12.2025

Press

Press

If you are a journalist and have any questions about ALK, please feel free to contact our Media Relations teams.

The press releases in this press room contain information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.

 

Latest news

News

  • Post date
    05/04/2026
    Three-month interim report (Q1) 2026 (unaudited)
  • Post date
    05/04/2026
    ALK upgrades its full-year outlook
  • Post date
    04/28/2026
    Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026
  • Post date
    04/20/2026
    ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
  • Post date
    04/15/2026
    neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada
  • Post date
    04/08/2026
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
  • Post date
    04/01/2026
    Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
  • Post date
    03/31/2026
    EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis
  • Post date
    03/16/2026
    Annual General Meeting in ALK-Abelló A/S held on 16 March 2026
Facts and guidelines

 


About ALK


Logo, fonts and images


Contact Media Relations


 

Photo library
Executive Leadership Team

Peter Halling, President & CEO


Claus Steensen Sølje, CFO


Edward Jordan, EVP Commercial Operations North America


Flora Beiche-Scholz, EVP Commercial Operations Europe


 


Lika Thiesen, EVP Global People & Organisation


Christian G. Houghton, EVP Product Supply


Jacob Glenting, EVP Corporate, Portfolio & Product Strategy


Jan Engel Jensen, SVP Global Quality

Headquarters & facilities


ALK headquarters


Production facilities, Hørsholm


Production facilities, Hørsholm


Production facilities, Hørsholm

Last updated: 01.04.2026

Our company

Our company

At ALK, we are pioneers in allergy with more than a century of experience under our belt.

ALK is a Denmark-based, global specialty pharmaceutical company focused on allergy. For over a century, we have been at the forefront of long-term allergy treatment and innovation, working with passion and dedication to help people living with this chronic disease, their families and the healthcare professionals who treat them.

We are present in 46 markets worldwide, with offices in more than 20 countries and production sites in the USA, Spain, France, and Denmark. Our global presence reflects our commitment to address allergy across the world. Currently, we reach 3.1 million patients annually worldwide.

Our approximately 2,800 employees have entered the second century of ALK’s existence with a unified mission: to help five million people living with allergies by 2030 through continuous growth and innovation.

Find our latest

news and contact

information for

our Media

Relations here

We’re on a purposeful mission

Allergy is a widespread, chronic disease impacting and challenging the lives of millions of adults and children globally every day. In fact, it is estimated to affect one in four people in the industrialised world.






 

Working with nature on a foundation of scientific expertise

Building on our deep understanding of the biological mechanisms behind allergies, we have developed a range of allergy immunotherapy treatments and management solutions that form the core of our current product portfolio.

A key component of these products is natural allergens, such as grass pollen and house dust mites. At ALK, we grow, collect, and harvest tons of these natural raw materials annually at our production facilities and take them through rigorous analysis, standardisation, and quality controls. We call this unique process “From farm to pharma”.

With our commitment to scientific progress, we are driven to continuously innovate and introduce groundbreaking concepts in allergy research and treatment, within our primary scientific focus areas; respiratory allergies, food allergies, anaphylaxis, and adjacent diseases.

Learn more about our scientific expertise and focus areas here.
Discover more about our unique production processes here.

Our leadership

Visit our

Investor site

to learn more about e.g.

our corporate governance,

relevant policies

and financial

reporting

At ALK, we have a two-tier leadership structure, consisting of a Board of Directors and an Executive Leadership Team (ELT). The board and the ELT are independent of each other.

Find more information about the Board of Directors at ALK on our Investor site here.


 

Our Executive Leadership Team

The Executive Leadership Team at ALK includes the following executives. You can find their photos for download under Press and learn more about each member of the team on our career site.


Peter Halling, President & CEO*


Claus Steensen Sølje, CFO*


Edward Jordan, EVP Commercial Operations North America


Flora Beiche-Scholz, EVP Commercial Operations Europe


 


Lika Thiesen, EVP Global People & Organisation


Christian G. Houghton, EVP Product Supply


Jacob Glenting, EVP Corporate, Portfolio & Product Strategy


Jan Engel Jensen, SVP Global Quality


 

* These two members of the Executive Leadership Team are registered with the Danish Business Authority and legally constitute ALK’s Board of Management.

Image description
 

The history of ALK is a history of ‘firsts’. Decades of pushing boundaries and raising standards have placed us at the forefront of our industry and for more than 100 years, we have consistently devised and developed major advances for the treatment of allergy.

Ever since 1923, when pharmacist Peter Barfod and physician Kaj Baagøe documented the first pharmaceutically manufactured allergy preparation, ALK has led the way in allergy treatment, and our history includes demonstrating how to manufacture allergen extracts, establishing a standardised method for large-scale manufacturing, and introducing new, more convenient treatment formulations.

In 2005, ALK became a listed company. Although traded on the NASDAQ Copenhagen (OMX: ALK B), ALK has an unusually stable ownership, with two shareholders having notified shareholdings of 5% or more. By supporting independent research at the highest level, our owners strive to significantly improve people’s health and well-being.

The Lundbeck Foundation, one of Denmark’s largest enterprise foundations, is the controlling shareholder of ALK, holding 67% of the votes and 40% of the capital.

Learn more about the first 100 years of our history:


Listen to our true crime documentary podcast e.g. on Spotify or Apple Podcasts

 
  • June, 1923
    ALK’s foundation
    On 9 June 1923, Doctor Kaj Baagøe and pharmacist Peter Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at Copenhagen University Hospital.
  • June, 1949
    Dedicated facilities
    The production of allergy immunotherapy treatments and diagnostics is centered at an independent unit called Allergologisk Laboratorium København (Allergological Laboratory Copenhagen).
  • June, 1972
    Technical advancements
    ALK develops the technique to accurately identify the proteins that provoke allergies.
  • June, 1976
    A new industry standard
    Based on the technique to identify the allergy-triggering proteins accurately, ALK develops a standardised process for manufacturing allergen extracts.
  • June, 1978
    A world’s first
    The world’s first standardised allergy immunotherapy product is launched by ALK.
  • June, 1989
    New owner
    The Lundbeck Foundation becomes the major shareholder of ALK. The foundation awards research grants primarily to support research in the biomedical sciences.
  • June, 1990
    A new treatment option
    ALK launches the world’s first sublingual allergy immunotherapy drops.
  • June, 1992
    Merging expertise
    ALK merges with rival Spanish company Abelló to become ALK-Abelló.
  • June, 2006
    A revolutionary ‘first’
    ALK has the world’s first sublingual allergy immunotherapy tablet approved in Europe.
  • June, 2008
    New name and logo
    ALK changes its name to ALK, referring to Allergological Laboratory Copenhagen, and introduces a new logo. ALK-Abelló remains the legal name of the company.
  • June, 2010
    Expanding in anaphylaxis
    ALK launches its first adrenaline 
autoinjector.
  • June, 2017
    Inclusion in GINA
    For the first time, allergy immunotherapy is recommended as a treatment option in the Global Initiative for Asthma (GINA) strategy document.
  • June, 2018
    A digital universe
    ALK’s digital patient engagement platform, klarify.me, is launched, offering a broad range of services to help people manage their allergies.
  • June, 2021
    Entering into food allergies
    ALK announces an entry into food allergy treatment and begins the development of a sublingual immunotherapy tablet 
for peanut allergies.
  • June, 2023
    ALK turns 100 years
    On 9 June 2023, ALK celebrated its 100-year anniversary, marking that the company has been a pioneer in fighting allergies for 100 years – and still counting.
  • June, 2024
    A new corporate strategy: Allergy+
    With a mission to help even more people, with more solutions, more efficiently, ALK entered its second century, launching a new strategy: Allergy+ and also entered into the largest in-licensing deal in the history of the company to help many more people with allergy and anaphylaxis
  • June, 2025
    A world’s first within anaphylaxis
    ALK launches a nasal adrenaline spray for the treatment of anaphylaxis - the first in the world – in e.g. Germany, and the UK. At the same time, the company launched its allergy immunotherapy tablets for the treatment of children in more than 20 markets.
ALK’s foundation On 9 June 1923, Doctor Kaj Baagøe and pharmacist Peter Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at Copenhagen University Hospital. 1923-06-08
Dedicated facilities The production of allergy immunotherapy treatments and diagnostics is centered at an independent unit called Allergologisk Laboratorium København (Allergological Laboratory Copenhagen). 1949-06-08
Technical advancements ALK develops the technique to accurately identify the proteins that provoke allergies. 1972-06-08
A new industry standard Based on the technique to identify the allergy-triggering proteins accurately, ALK develops a standardised process for manufacturing allergen extracts. 1976-06-08
A world’s first The world’s first standardised allergy immunotherapy product is launched by ALK. 1978-06-08
New owner The Lundbeck Foundation becomes the major shareholder of ALK. The foundation awards research grants primarily to support research in the biomedical sciences. 1989-06-08
A new treatment option ALK launches the world’s first sublingual allergy immunotherapy drops. 1990-06-08
Merging expertise ALK merges with rival Spanish company Abelló to become ALK-Abelló. 1992-06-08
A revolutionary ‘first’ ALK has the world’s first sublingual allergy immunotherapy tablet approved in Europe. 2006-06-08
New name and logo ALK changes its name to ALK, referring to Allergological Laboratory Copenhagen, and introduces a new logo. ALK-Abelló remains the legal name of the company. 2008-06-08
Expanding in anaphylaxis ALK launches its first adrenaline 
autoinjector. 2010-06-08
Inclusion in GINA For the first time, allergy immunotherapy is recommended as a treatment option in the Global Initiative for Asthma (GINA) strategy document. 2017-06-08
A digital universe ALK’s digital patient engagement platform, klarify.me, is launched, offering a broad range of services to help people manage their allergies. 2018-06-08
Entering into food allergies ALK announces an entry into food allergy treatment and begins the development of a sublingual immunotherapy tablet 
for peanut allergies. 2021-06-08
ALK turns 100 years On 9 June 2023, ALK celebrated its 100-year anniversary, marking that the company has been a pioneer in fighting allergies for 100 years – and still counting. 2023-06-08
A new corporate strategy: Allergy+ With a mission to help even more people, with more solutions, more efficiently, ALK entered its second century, launching a new strategy: Allergy+ and also entered into the largest in-licensing deal in the history of the company to help many more people with allergy and anaphylaxis 2024-06-08
A world’s first within anaphylaxis ALK launches a nasal adrenaline spray for the treatment of anaphylaxis - the first in the world – in e.g. Germany, and the UK. At the same time, the company launched its allergy immunotherapy tablets for the treatment of children in more than 20 markets. 2025-06-08
  • ALK’s foundation
    1923-06-08
    On 9 June 1923, Doctor Kaj Baagøe and pharmacist Peter Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at Copenhagen University Hospital.
  • Dedicated facilities
    1949-06-08
    The production of allergy immunotherapy treatments and diagnostics is centered at an independent unit called Allergologisk Laboratorium København (Allergological Laboratory Copenhagen).
  • Technical advancements
    1972-06-08
    ALK develops the technique to accurately identify the proteins that provoke allergies.
  • A new industry standard
    1976-06-08
    Based on the technique to identify the allergy-triggering proteins accurately, ALK develops a standardised process for manufacturing allergen extracts.
  • A world’s first
    1978-06-08
    The world’s first standardised allergy immunotherapy product is launched by ALK.
  • New owner
    1989-06-08
    The Lundbeck Foundation becomes the major shareholder of ALK. The foundation awards research grants primarily to support research in the biomedical sciences.
  • A new treatment option
    1990-06-08
    ALK launches the world’s first sublingual allergy immunotherapy drops.
  • Merging expertise
    1992-06-08
    ALK merges with rival Spanish company Abelló to become ALK-Abelló.
  • A revolutionary ‘first’
    2006-06-08
    ALK has the world’s first sublingual allergy immunotherapy tablet approved in Europe.
  • New name and logo
    2008-06-08
    ALK changes its name to ALK, referring to Allergological Laboratory Copenhagen, and introduces a new logo. ALK-Abelló remains the legal name of the company.
  • Expanding in anaphylaxis
    2010-06-08
    ALK launches its first adrenaline 
autoinjector.
  • Inclusion in GINA
    2017-06-08
    For the first time, allergy immunotherapy is recommended as a treatment option in the Global Initiative for Asthma (GINA) strategy document.
  • A digital universe
    2018-06-08
    ALK’s digital patient engagement platform, klarify.me, is launched, offering a broad range of services to help people manage their allergies.
  • Entering into food allergies
    2021-06-08
    ALK announces an entry into food allergy treatment and begins the development of a sublingual immunotherapy tablet 
for peanut allergies.
  • ALK turns 100 years
    2023-06-08
    On 9 June 2023, ALK celebrated its 100-year anniversary, marking that the company has been a pioneer in fighting allergies for 100 years – and still counting.
  • A new corporate strategy: Allergy+
    2024-06-08
    With a mission to help even more people, with more solutions, more efficiently, ALK entered its second century, launching a new strategy: Allergy+ and also entered into the largest in-licensing deal in the history of the company to help many more people with allergy and anaphylaxis
  • A world’s first within anaphylaxis
    2025-06-08
    ALK launches a nasal adrenaline spray for the treatment of anaphylaxis - the first in the world – in e.g. Germany, and the UK. At the same time, the company launched its allergy immunotherapy tablets for the treatment of children in more than 20 markets.

You might want to learn more about:

Last updated: 01.04.2026

Nine-month interim report (Q3) 2025 (unaudited)

Last updated: 12.11.2025

Careers

Careers at ALK

Join us on our purposeful mission to help people living with allergy worldwide.

ALK is a global specialty pharmaceutical company focused on allergy. For more than a century, we’ve been at the forefront of long-term allergy treatment, with a strong focus on innovation. We’ve entered our second century as a global pioneer in the field of allergy with an ambition to continue our growth and a mission to help five million people living with allergies by 2030.

With our roots and headquarter in Denmark, ALK employs around 2,800 people worldwide and we’re always on the lookout for new colleagues to join us within different parts of our organisation and with different backgrounds.

We invite you to explore our current career opportunities and join a team that values collaboration, innovation, and a shared commitment to helping people affected by allergies worldwide.

Explore current

opportunities at

ALK for a career

guided by a

strong purpose.

This is ALK

Allergy impacts and challenges the lives of millions of adults and children every day. At ALK, our purpose is to improve the lives of people living with allergies. Building on our strong heritage, we are guided by our strategy, Allergy+, that shows us a clear path towards this goal through focus, innovation, cultivation and optimisation. 

More than a century of scientific expertise

Our comprehensive knowledge of the biological mechanisms behind allergy has laid the groundwork for creating a variety of allergy immunotherapy treatments and management solutions, which are central to our current product lineup.

We are dedicated to furthering scientific advancements and consistently introducing new concepts in allergy research and treatment. Our scientific efforts primarily focus on respiratory allergy, food allergy, anaphylaxis, and adjacent disease areas.

Learn more about our scientific expertise and focus areas here.

Working with nature – from farm to pharma

The main ingredients in our allergy immunotherapy products at ALK, are natural allergens, such as grass pollen and house dust mites. Each year, we grow, collect and harvest tons of these raw materials at our production facilities. Handling natural allergens requires thorough analysis, standardisation and quality control processes to ensure that biological variations do not impact the product quality. Watch the video to learn more about how we harness nature for our allergy immunotherapy products – We call it “from farm to pharma”.

Helping people across the globe

With production sites in the USA, Spain, France and Denmark, and with offices in more than 20 countries worldwide, our global workforce prioritise collaboration across borders and functions to reach people with allergy in 46 markets.

Find our current opportunities at your preferred location here.

Learn more about our global presence and our company here.

A culture of collaboration and inclusion

As a global company, we’re committed to fostering a working environment characterised by cross-cultural collaboration and inclusion where every employee can thrive and develop in their career journey. We find it essential for our continued ability to innovate and help people across the globe.

To cultivate our inclusive environment, we focus on training our leaders in cultural awareness and inclusive leadership, promoting an unbiased mindset in recruitment processes, and launching awareness campaigns that highlight inclusion as a vital driver of engagement.  

Our company size allows for meaningful involvement of employees across the organisation and means that each individual’s contributions make a significant impact on our success as we grow as an organisation.

Guided by our three Cultural Beliefs — Do the Right Thing, Pursue Growth, and Build Bridges — we empower each other to perform our best every day as we strive to develop innovative allergy treatments for people with allergy worldwide. We encourage open dialogue and involvement and we work to ensure that everyone feels valued.

And we’re committed to doing it all in a sustainable manner. You can learn more about our efforts and ambitions within environmental, social and governance sustainability practices a here.

Our business functions

Previous
  • Avatar

    Research and Development

    At the core of ALK, innovation thrives. Our R&D function develops world class therapies for allergy management in a collaborative environment. Fostering new insights into research, this function is shaping the future of allergy treatment.

  • Avatar

    Product Supply

    ALK's Product Supply team helps ensure smooth global delivery of allergy treatments from our manufacturing sites spread across Europe and the USA. Their focus is on meeting market needs and demands, while collaborating as a dynamic and international Product Supply team.

  • Avatar

    Global Quality

    In our Global Quality team, colleagues worldwide are ensuring the highest standards in product safety and efficiency, driving continuous improvements and compliance across the organisation.

  • Avatar

    Commercial Operations

    ALK's passionate Commercial Operations team drive our international sales growth with a strong focus on our purpose to help adults and children with allergy. If you thrive in a professional sales focused environment this team is for you.

  • Avatar

    People & Organisation

    People & Organisation is a global team, driving a thriving workplace culture across borders and functions, supporting employee development, and enhancing engagement for all ALK colleagues. This function covers the areas of Human Resources, Corporate Communications, and Sustainability.

  • Avatar

    Global Business Support

    At ALK, our Global Business Support function covers the areas IT, Corporate Affairs & Legal, Finance, Procurement, and Investor Relations. Across the function, colleagues collaborate to ensure the necessary foundation for our global teams to succeed in shaping the future of allergy treatments.

  • Avatar

    Global Strategy & Corporate Development

    The Global Strategy & Corporate Development team shape ALK's future direction, drive strategic initiatives, and foster impactful partnerships and collaborations that enhance our growth and enable us to help more people with allergy.

Next

Meet your future colleagues

We strive to bring together a diverse group of individuals and to ensure that every employee feels valued, respected, and safe to be their authentic selves at work.

Below, you can get to know some of our talented employees, helping to ensure that ALK stays in the forefront of allergy research and solutions. Explore the presentations below to discover their stories, insights, and career paths, all reflecting our vibrant workplace culture and collaborative spirit.

Previous
  • Avatar

    Magnus

    Magnus Lindqvist joined ALK Sweden in 2003 after earning his Master's in Zoophysiology. He progressed from sales representative to Medical Science Liaison, where he blends scientific expertise with sales experience: “A career at ALK offers many opportunities for development. If you bring the drive, ALK will support your journey.”


  • Nicoline

    Nicoline Mi Jung Kirk joined ALK in 2021 as Global Marketing Program Leader, drawn by our strong purpose. Today, she’s the Associate Director of Global Marketing Projects. She thrives in ALK's collaborative culture and has already led several strategic projects across functions and regions, significantly contributing to our mission to help 5 million people with allergies by 2030.

  • Avatar

    Andrew

    Before joining ALK Oklahoma in 2022, Andrew O'Keefe spent years in the oil industry. He sought a purpose-driven role that offered a better work-life balance. At ALK, he found both – contributing to allergy care while embracing a collaborative culture. Andrew aims to advance automation and innovative technologies in our production processes


  • Lika

    Lika Thiesen joined ALK in 2024 as Executive Vice President of Global People and Organisation, leading a team that has a significant impact on our workplace: “I believe it’s essential to create an environment where all employees feel included and empowered. I’m passionate about supporting professional development and establishing clear paths for growth within the organisation.”

  • Avatar

    Neera

    Neera Chakrapani joined ALK in  2023 as a postdoctoral researcher in Global Research and Drug Discovery. Today Neera develops diagnostic methods. In her role, Neera also collaborate with universities, and her research is already impacting allergy treatment. She values ALK’s culture, teamwork and open dialogue, and is excited to make a meaningful impact in allergy research.

  • Avatar

    Isabel

    Isabel Courinha Martinho joined ALK Spain in 1985 after graduating as a nurse. She wanted to work with people and help improve their health, and joined ALK as a research assistant. Since then, she has evolved into holding key roles in medical marketing and regulatory affairs: “ALK provides a supportive environment for continuous learning. The opportunities I've been given to explore and grow have been immensely rewarding.”


  • Ihor Mycak

    With a natural passion for innovation and optimisation, Ihor Mycak has grown his career from his original field of expertise within finance to a leading role in commercial excellence since joining ALK in 2014. As Head of Global Commercial Excellence, Ihor drives impactful projects like integrating global commercial data platforms and accelerating smarter, faster decision-making. Ihor’s work and drive for pace play a key role in advancing ALK’s efforts towards our ambitious mission of helping 5 million people with allergy annually by 2030.

  • Avatar

    Tomasz

    Tomasz Ryś joined ALK Poland in 2018. In Global Finance's Product Supply team, he aims to find optimisation opportunities by helping product supply and finance speak the same language. Since his entry to the company, Tomasz has taken on increasing responsibilities, leading significant standardisation projects and implementing vital performance reports: “If you want to grow within a supportive, innovative company, ALK is the place to be."


  • Cecilia

    Cecilia Rossetti has a passion for science and for making a difference in healthcare. With a master’s degree in analytical chemistry from her home country, Italy, and a PhD in pharmaceutical chemistry from Norway, she has a strong expertise in proteomics and mass spectrometry. Cecilia joined ALK in 2022, and today, as a Senior Lead Scientist, she leads innovative allergy research projects at ALK, ranging from phase 2 studies to early discovery initiatives with the potential to find innovative ways to address allergy in the future.

Next
 

Meet our leaders

Dive into the videos below to learn more about the people behind the titles in our Executive Leadership Team at ALK.

Peter Halling

Claus Steensen Sølje

Christian G. Houghton

Lika Thiesen


 

Jacob Glenting

Jan Engel Jensen

xxxxxxx

xxxxxxx

If ALK sounds like a place for you, we hope you will check out our current opportunities here.

Last updated: 01.04.2026

Symposium on Specific Allergy SOSA

Healthcare professionals

Symposium on 
Specific Allergy SOSA

Symposium on Specific Allergy

Symposium on Specific Allergy (SOSA) is a global forum dedicated to advancing knowledge about specific allergies.

Since 1994, SOSA has been conducted in physical, virtual, and hybrid formats, engaging over 25,000 healthcare professionals worldwide.

SOSA focuses on delivering comprehensive content that closely aligns with the latest developments in allergy research. SOSA has been fortunate to feature esteemed presenters who are leading experts in their respective fields, representing a global network to ensure thorough and impactful knowledge sharing.

The symposia have varied in length, ranging from half a day to two days depending on the format. By attending the symposium, participants have had the opportunity to earn CME credits.

You can find an overview of previous SOSAs, along with examples of previously presented programmes here.

Main objectives of SOSA

Foster ongoing dissemination of scientific knowledge to enhance outcomes for patients with allergy

Provide key updates on recent advancements in allergic diseases and encourage scientific discussions

Facilitate the optimisation of clinical practice aimed at improving outcomes for allergic patients


Expand scientific knowledge
Enhance the understanding of allergies and the treatments through scientific insights

Increase treatment awareness
Equip healthcare providers with the tools to effectively communicate all available treatment options to patients, facilitating informed decision-making

Continuous engagement
Establish opportunities for meaningful interactions and sustained engagement among healthcare professionals globally

Global expertise to local impact
Facilitate broader access to events and educational activities to enrich knowledge and peer-to-peer medical collaboration

Previous SOSAs

SOSA is a unique global medical forum for specific allergies and has been held as in-person, hybrid, and virtual formats since 1994, with support from ALK. Previous SOSA-sessions will be made available on ALK Pro Global

SOSA 2021
SOSA 2015
SOSA 2023 Copenhagen
SOSA 2023 Copenhagen
SOSA 2023 Copenhagen
Last updated: 25.09.2025

Privacy notice - shareholders, proxies and advisors

Privacy notice for shareholders, proxies and advisors

March 2025

The purpose of this privacy notice is to describe how ALK-Abelló A/S (ALK), as part of its handling of investor relations, collects, processes and stores personal data about its shareholders, proxies, and advisors, including registration in the register of shareholders and the convening and holding of Annual General Meetings. In addition, this privacy notice aims to provide information about your rights under the General Data Protection Regulation (GDPR). Your privacy is important to ALK.

1. Identity and contact details of the data controller

The legal entity responsible for processing your personal data is:

 

ALK-Abelló A/S

Address: Bøge Allé 1

2970 Hørsholm

Denmark

Tel.: +45 45747576

Email: data.protection@alk.net

 

Our Data Protection Officer:

Bech-Bruun Advokatpartnerselskab

CVR nr.: 38538071

Gdanskgade 18

2150 Nordhavn

Denmark

Tel.: +45 72 27 30 02

Email: dpo.alk@bechbruun.com

Encrypted email via: https://dpo.bechbruun.com/alk

 

If you have any questions regarding the processing of your personal data, you can always reach out to ALK or our Data Protection Officer.

2. Detailed information on the processing carried out by ALK

We process your personal data to comply with the legal obligations set out in corporate laws, as well as announcements to the Danish Financial Supervisory Authority and Nasdaq Copenhagen.

In connection with ALK’s Annual General Meeting, ALK collects, stores, and processes the personal data. This occurs in different respects, as follows:

Purpose: Identification of shareholders and maintenance of the register of shareholders, including the shareholder portal.

ALK will collect and process information about each shareholder, including:

  • Name, email address, home address
  • Portfolio of shares, voting rights, date of acquisition/sales
  • Username and password, account number with VP securities, investor ID and custodian bank

 

Lawfulness of Processing: ALK processes personal data in accordance with:

  • Article 6(1)(c) of GDPR to comply with obligations and shareholder’s rights set out in section 50 of the Danish Companies Act
  • Article 6(1)(f) of GDPR for shareholders identification to be able to answer their request and to communicate with them (legitimate interest)

 

Storage period:

ALK will retain your personal data for up to 5 years plus the current financial year after you no longer own shares in ALK.


 

Purpose: Convening and the holding of the Annual General Meetings.

ALK will process personal data to invite shareholders to the Annual General Meetings and enable them to exercise their rights at the meetings, issue proxies, and vote by post.

ALK processes personal data from shareholders' advisors so that the advisor can attend the Annual General Meeting. In addition, ALK processes this information to issue admission cards to shareholders, proxies, and advisors.

ALK will collect and process information about each shareholder, including:

  • Name, email address, home address
  • Attendance at the Annual General Meeting, advisor’s attendance at the meeting
  • Proxies, votes cast, including vote by post and portfolio of shares

 

Lawfulness of Processing: ALK processes personal data in accordance with:

  • Article 6(1)(c) of GDPR to comply with legal obligations in section 93 of the Danish Companies Act

 

Storge period:

ALK will keep your personal data for up to 5 years plus the current financial year after you no longer own shares in ALK.

The notice, including the agenda with complete proposals and certain auxiliary documents (such as, but not limited to, proxy forms and correspondence voting forms), is published as a company announcement through Nasdaq Copenhagen and on ALK’s website. It is also distributed by email to shareholders who have requested it and will remain publicly available on our website for fifteen years.

Additionally, ALK may retain the notice, agenda, and auxiliary documents for as long as necessary to protect and pursue the interests of ALK and its shareholders. Materials documenting the company’s history, decisions made, etc., are retained for as long as ALK exists.


 

Purpose: Screening of individuals subject to EU, UK, or US sanctions.

ALK is legally obligated to ensure that individuals subject to economic sanctions imposed by the European Union, the United Kingdom, or the United States of America do not exercise shareholder rights during the Annual General Meeting. To fulfil this obligation, ALK may process personal data of shareholders participating in the Annual General Meeting by screening their information against relevant sanctions lists.

ALK will process the following personal data of shareholders based on information registered in the shareholder register:

  • Name and home address

 

Lawfulness of Processing: ALK processes personal data in accordance with:

  • Article 6(1)(c) of GDPR to comply with applicable sanctions laws and regulations, which include preventing sanctioned individuals from exercising shareholder rights.
  • Article 6(1)(f) of GDPR as ALK has a legitimate interest in ensuring compliance with international sanctions regimes, maintaining corporate integrity, and mitigating legal and financial risks.

 

Storage period:

Personal data collected and processed for sanctions screening will be retained only for as long as necessary to fulfil the legal obligations and purposes stated above.


 

Purpose: Confirmation of standing for election.

Persons standing for election at the Annual General Meeting must confirm their eligibility, along with information about other managerial responsibilities.

In this context, and for the purpose of verifying the candidate’s identity and eligibility, ALK will collect and process personal data, including the candidate’s name and managerial positions held.

 

Lawfulness of Processing: ALK processes personal data in accordance with:

  • Article 6(1)(c) of GDPR to comply with Danish corporate law as set out in section 112 of the Danish Companies Act
  • Article 6(1)(f) of GDPR for processing personal data to ensure transparency in corporate governance, facilitate the election process, and enable subsequent regulatory registrations (legitimate interest)

 

Storage period:

Personal data collected and processed will be retained for as long as necessary to protect and pursue the interests of ALK and its shareholders.


 

Purpose: Submitting questions and proposals prior to the Annual General Meeting, handling of questions and exercising the right to speak at the Annual General Meeting as well as preparation of the minutes of the Annual General Meeting.

If questions are answered in writing prior to the Annual General Meeting, ALK will process your information in order to present the questions, answers, and the name of the person who submitted the question at the Annual General Meeting.

If a proposal regarding a specific issue is included on the agenda for the Annual General Meeting, ALK will process the name of the person and the proposal.

If you exercise your right to speak, your personal information will be recorded in the minutes.

Lawfulness of Processing: ALK processes personal data in accordance with

  • Article 6(1)(c) of GDPR to comply with legal obligations on section 78, 90, and 101 of the Danish Companies Act
  • Article 6(1)(f) of GDPR (legitimate interest) to be able to identify shareholders and proxies in order for them to present proposals and questions prior to and during the Annual General Meeting and to exercise their right to speak

Storage period

  • ALK will store minutes of the Annual General Meeting until it is no longer necessary for ALK to protect ALK and shareholder’s interest, including for the purpose of documenting the deliberations and resolutions passed at Annual General Meeting.

 

Purpose: Audio and/or visual recording.

General Annual Meetings are audio and/or visually recorded, and ALK may webcast the Annual General Meeting and maintain a recording on ALK’s webpage.

ALK will process your personal data, such as your voice and image, if you exercise your right to speak during the Annual General Meeting.

The recording will include the agenda (including proposals from shareholders) and may also capture questions or statements submitted in writing during the meeting.

Lawfulness of processing: ALK processes your personal data in accordance with

  • Article 6(1)(f) of GDPR (legitimate interest) in processing the recordings to use them to prepare the minutes and in documenting the proceedings at the Annual General Meeting and making it available to shareholders and media who are unable to attend or view the live webcast of the Annual General Meeting.

Storge period

  • ALK will keep a recording publicly available on demand on its website for a period of up to 5 years after the Annual General Meeting

3. Recipients of the personal data

i       ALK EMPLOYEES & EXTERNAL PROCESSORS

The recipients of your personal data will be employees of entities belonging to the ALK Group and external processors providing specific services while processing personal data on our behalf. They will receive your personal data only on a ‘need-to-know’ basis, subject to confidentiality obligations and after signing legal agreements. Furthermore, we may share your data with the general public through publication on ALK’s website in accordance with applicable law.

 

 

ii       INDEPENDENT THIRD PARTIES

When needed, we may disclose your personal data to third parties, such as Nasdaq Copenhagen A/S and Public Authorities, such as the Danish Business Authority, attorneys, or third-party auditors.

 

 

iii       TRANSFERS OF DATA FROM EU/EEA TO THIRD COUNTRIES

If we share data from the EU/EEA with a company or ALK affiliate in a third country, we will apply contractual clauses that meet EU standards to ensure the receiving company handles personal data appropriately, unless the country where the company operates is already deemed by the EU to offer an adequate level of data protection. More information about such clauses is available here. If data transfers are required in other situations, we will inform you about the specific compliance measures in place to enforce EU law.

4. Data Subject Rights

a) Right to access

     You have the right to request access to your personal data held by ALK, as well as additional details.

 

b) Right to rectification

      You have the right to request correction of inaccurate or incomplete personal data.

 

c) Right to erasure

     You have the right to request the deletion of your personal data, except when retention is required by       law.

 

d) Right to restrict processing

      You have the right to object to restriction of your personal data.

 

e) Right to object

      You have the right to object to the processing of your personal data.

 

f) Right to data portability

      In specific situations, you are entitled to receive your personal data in a structured, widely used, and        machine-readable format.

 

If you would like to exercise any of these rights, please contact us using the contact details provided in section 1.

5. Right to Complain

You have the right to file a complaint with the Data Protection Authority if you are dissatisfied with the way we process your personal data. Contact information of the Data Protection Authority can be found on their website.

If you have any questions or concerns about this privacy notice or our processing of your personal data, please contact us using the contact details provided in section 1.

Last updated: 10.03.2025

Testing components

Previous
  • Avatar

    Research and Development

    At the core of ALK, innovation thrives. Our R&D function develops world class therapies for allergy management in a collaborative environment. Fostering new insights into research, this function is shaping the future of allergy treatment.

  • Avatar

    Product Supply

    ALK's Product Supply team helps ensure smooth global delivery of allergy treatments, meeting market needs and demands, while collaborating as a dynamic and international Product Supply team

  • Avatar

    Global Quality

    In our Global Quality team, colleagues worldwide are ensuring the highest standards in product safety and efficiency, driving continuous improvements and compliance cross the organisation.

  • Avatar

    Commercial Operations

    ALK's passionate Commercial Operations team drive our international sales growth with a strong focus on our purpose to help adults and children with allergy. If you hrive in a professional sales focused environment this team is for you.

  • Avatar

    People & Organisation

    People & Organisation is a global team, driving a thriving workplace culture across borders and functions, supporting employee development, and enhancing engagement for all ALK colleagues

Next
Graph-left Graph-right
Graph-left Graph-right
Graph-left Graph-right

Henning Løwenstein contributed significantly to the identification, categorisation, isolation, characterisation, and nomenclature of allergens and allergen components, recombinant allergens, standardization of allergen extracts for diagnosis and treatment of allergic diseases as well as translation of research understandings into robust clinical trials.

To recognise this outstanding contribution, ALK established and dedicated The Henning Løwenstein Research Award to the researcher Henning Løwenstein on his 25th anniversary of working at the company.

Join this year's award ceremony live on 13 November at 15.00 p.m. CET right here! Use the password: ALKSOSA2025 to enter the livestreaming.


Expand scientific knowledge
Enhance the understanding of allergies and the treatments through scientific insights

Increase treatment awareness
Equip healthcare providers with the tools to effectively communicate all available treatment options to patients, facilitating informed decision-making

Continuous engagement
Establish opportunities for meaningful interactions and sustained engagement among Health Care Professionals globally, before and after the event through education

Global expertise to local impact
Facilitate broader access to events and educational activities to enrich knowledge and peer-to-peer medical collaboration
30 years of advancing allergy immunotherapy
Last updated: 03.11.2025

Governance

Corporate culture

Promoting a culture of transparency and accountability, ALK encourages employees, suppliers, vendors, consultants or others with a work-related relationship with ALK to raise serious and sensitive concerns using our whistleblower hotline, ALK Alertline.

We provide annual Code of Conduct training for all employees. In 2025, 99% (2024: 98%) of employees across all functions completed the training.

ALK Alertline
ALK's whistleblower hotline enables employees, business partners and other stakeholders to report any serious and sensitive concern in a confidential and anonymous manner.
Code of Conduct
ALK's Code of Conduct outlines the standards of behaviour that we expect from all ALK employees when interacting with stakeholders.

Animal welfare

When developing new treatments, we conduct tests on animals to ensure that patients receive safe and effective medicines. We only use animals for research purposes when no scientifically valid alternative exists.

In 2025, we introduced an animal welfare policy, formalising ou commitment to the highest standards of animal welfare within research and development activities.

We are committed to the 3R principles (Replace, Reduce, and Refine). All research complies with relevant national and international regulations, including the EU Directive on protection of animals used for scientific purposes, and Federation of European Laboratory Animal Science Associations (FELASA) guidelines, with equivalent standards upheld globally.

Code of Conduct
Anti-corruption Policy
Data Ethics Policy
Third party code of conduct
Tax policy
Whistleblower Policy
UK Modern Slavery Act statement 2025

Partnering for sustainability

The challenges of climate change require commitments and partnerships

Last updated: 20.02.2026